

PRODUCT MONOGRAPH

**PrPHARIXIA®**

**PrPHARIXIA® ALCOHOL FREE**

Benzylamine Mouthwash, BP

Benzylamine hydrochloride 1.5 mg/mL (0.15% w/v)

Buccal

**Local Analgesic**

**PENDOPHARM, Division of Pharmascience Inc.**  
6111 Royalmount Avenue Suite #100  
Montreal, Québec,  
H4P 2T4

Date of Revision:  
November 27, 2019

Submission Control No: 226851

® Registered Trademark of Pharmascience Inc.

## Table of Contents

<b>PART I: HEALTH PROFESSIONAL INFORMATION .....</b>	<b>3</b>
SUMMARY PRODUCT INFORMATION.....	3
INDICATIONS AND CLINICAL USE .....	3
CONTRAINDICATIONS .....	3
WARNINGS AND PRECAUTIONS.....	4
ADVERSE REACTIONS.....	4
DOSAGE AND ADMINISTRATION .....	4
OVERDOSAGE .....	4
ACTION AND CLINICAL PHARMACOLOGY .....	5
STORAGE AND STABILITY .....	5
DOSAGE FORMS, COMPOSITION AND PACKAGING .....	5
<b>PART II: SCIENTIFIC INFORMATION.....</b>	<b>7</b>
PHARMACEUTICAL INFORMATION .....	7
CLINICAL TRIALS .....	8
DETAILED PHARMACOLOGY.....	8
TOXICOLOGY .....	9
REFERENCES .....	11
<b>PART III: CONSUMER INFORMATION.....</b>	<b>13</b>

**PrPHARIXIA®**

**PrPHARIXIA® ALCOHOL FREE**

Benzydamine Mouthwash, BP

Benzydamine hydrochloride 1.5 mg/mL (0.15% w/v)

**PART I: HEALTH PROFESSIONAL INFORMATION**

**SUMMARY PRODUCT INFORMATION**

<b>Route of Administration</b>	<b>Dosage Form / Strength</b>	<b>All Nonmedicinal Ingredients</b>
Oral (Buccal)	Mouthwash / 1.5 mg/mL (0.15% w/v)	Alcohol, Citric Acid Anhydrous, Glycerin, Methylparaben, Natural and Artificial Mouthwash Aroma (Water, Ethyl Alcohol, Natural & Artificial flavour, Polysorbate, Propylene Glycol, D&C Yellow No. 10 and FD&C Blue No. 1), Polysorbate 80, Propylparaben, Purified Water, Sodium Citrate Dihydrate, Sorbitol Solution.
Oral (Buccal)	Mouthwash / 1.5 mg/mL (0.15% w/v) (Alcohol-Free)	Citric Acid Anhydrous, Glycerin, FD&C Yellow No. 6, FD&C Red No. 40, Methylparaben, Natural Orange Flavour (contains Modified Corn Starch, Corn Syrup, Maltodextrin, Citric Acid, BHT), Polysorbate 80, Propylparaben, Purified Water, Sodium Citrate Dihydrate, Sorbitol Solution.

**INDICATIONS AND CLINICAL USE**

PHARIXIA® and PHARIXIA® ALCOHOL FREE (benzydamine hydrochloride) are indicated for the relief of pain in acute sore throat and for the symptomatic relief of oro-pharyngeal mucositis caused by radiation therapy.

**CONTRAINDICATIONS**

Benzydamine hydrochloride is contraindicated in subjects with a history of hypersensitivity to any ingredient in the formulation or component of the container. For a complete listing, see the Dosage Forms, Composition and Packaging section of the product monograph.

## **WARNINGS AND PRECAUTIONS**

The use of undiluted PHARIXIA<sup>®</sup> and PHARIXIA<sup>®</sup> ALCOHOL FREE may produce local irritation manifested by burning sensation in patients with mucosal defects. If necessary, it may be diluted (1:1) with lukewarm water.

### **Renal**

Since benzydamine hydrochloride is absorbed from oral mucosa and then excreted mostly unchanged in the urine, a possibility of its systemic action has to be considered in patients with renal impairment.

### **Pregnant Women**

The safety of benzydamine hydrochloride has not been established in pregnant patients. Risk to benefit ratio should be established if PHARIXIA<sup>®</sup> and PHARIXIA<sup>®</sup> ALCOHOL FREE is to be used in these patients.

### **Pediatrics**

Safety and dose directions have not been established for children five years of age and younger.

## **ADVERSE REACTIONS**

The most frequent adverse reactions reported are: local numbness (9.7%), local burning or stinging sensation (8.2%), nausea and/or vomiting (2.1%).

The least frequent were reports of throat irritation, cough, dryness of the mouth associated with thirst, drowsiness and headache.

## **DOSAGE AND ADMINISTRATION**

Not less than 15 mL of the liquid should be used for each gargle or rinse and repeated three or four times a day, depending on the severity of the treated condition.

The liquid should be kept in contact with the inflamed mucosa for at least 30 seconds and then expelled from the mouth. Administration should begin the day prior to commencement of radiation therapy and continue daily during the treatment period as well as after cessation of radiation applications until desired improvement is obtained.

In Acute Sore Throat: gargle with 15 mL every 1.5 to 3 hours. The solution should be expelled from the mouth after use.

## **OVERDOSAGE**

For management of a suspected drug overdose; contact your regional Poison Control Centre.

There are no known cases of overdosage with Benzydamine Mouthwash. Since no specific antidote for benzydamine is available, cases of excessive ingestion of the liquid should receive supportive symptomatic treatment aimed at rapid elimination of the drug.

## **ACTION AND CLINICAL PHARMACOLOGY**

Animal studies using the parenteral route have shown that benzydamine hydrochloride possesses properties of an analgesic/anti-inflammatory agent. This effect is not mediated through the pituitary-adrenal axis. Studies using the topical route have demonstrated local anesthetic properties of benzydamine hydrochloride. In controlled studies in humans with oro-pharyngeal mucosity due to radiation therapy, benzydamine hydrochloride use has provided relief through reduction of pain and edema. Similar studies in patients with acute sore throat demonstrated relief from pain.

Benzydamine hydrochloride has been detected in blood and urine after gargling four times for 20 seconds, in rapid succession, each time with a volume equivalent to 25.5 mg benzydamine per 70 kg body weight (approximately 17 mL per gargle). The average maximum plasma level of 59 ng/mL (range 17 to 173) was obtained 2 hours after ingestion. For comparison, one dose of 17 mL, when swallowed, yielded an average maximum plasma level of 180 ng/mL (range 102 to 324), also at 2 hours after ingestion. Benzydamine was still detectable 24 hours later in 7 out of 10 subjects after gargling (average plasma level of 7 ng/mL) and in 9 out of 10 subjects after the ingestion (average 32 ng/mL).

The urinary excretion was completed within 3-4 days after the single dose in both groups; about 46% of the dose was recovered in garglers, and 26% in ingestors. Repeated administration for 7 days did not result in a significant accumulation of benzydamine hydrochloride in plasma.

## **STORAGE AND STABILITY**

Store at room temperature (15°C to 30°C).

## **DOSAGE FORMS, COMPOSITION AND PACKAGING**

PHARIXIA® (1.5 mg/mL; 0.15% (w/v) mouthwash) is available in PET bottles containing 250 mL of a clear, yellow-green liquid with a distinctive mint-like odour.

Nonmedicinal Ingredients: Alcohol, Citric Acid Anhydrous (for pH adjustment), Glycerin, Methylparaben, Natural and Artificial Mouthwash Aroma, Polysorbate 80, Propylparaben, Purified Water, Sodium Citrate Dihydrate (for pH adjustment), Sorbitol Solution.

*Natural and Artificial Mouthwash Aroma contains: Water, Ethyl Alcohol, Natural & Artificial flavour, Polysorbate, Propylene Glycol, D&C Yellow No. 10 and FD&C Blue No. 1*

PHARIXIA® ALCOHOL FREE (1.5 mg/mL; 0.15% (w/v) mouthwash) is available in PET bottles containing 250 mL of a clear light-orange solution.

Nonmedicinal Ingredients: Citric Acid Anhydrous (for pH adjustment), Glycerin, FD&C Yellow No. 6, FD&C Red No. 40, Methylparaben, Natural Orange Flavour, Polysorbate 80, Propylparaben, Purified Water, Sodium Citrate Dihydrate (for pH adjustment), Sorbitol Solution.

*Natural Orange Flavour contains: Modified Corn Starch, Corn Syrup, Maltodextrin, Citric Acid, BHT*

## PART II: SCIENTIFIC INFORMATION

### PHARMACEUTICAL INFORMATION

#### Drug Substance


Proper name: Benzydamine hydrochloride

Chemical names: 1) 1-Propanamine, *N,N*-dimethyl-3-[[1-(phenyl-methyl)-1*H*-indazol-3-yl]oxy]-, monohydro chloride.  
2) 1-Benzyl-3-[3-dimethyl-amino)propoxy]-1*H*-indazole monohydrochloride.

Molecular formula:  $C_{19}H_{23}N_3O \cdot HCl$

Molecular mass: 345.87

Structural formula:



Melting Point: 157°C - 160°C

Physicochemical properties:

Physical description: White to creamy-white, crystalline powder.

Solubility: Freely soluble in water, alcohol, methanol and chloroform.  
Slightly soluble in acetone and practically insoluble in ether.

pH: Between 4.5 and 5.5 (3% H<sub>2</sub>O)

## **CLINICAL TRIALS**

In controlled studies in humans with oro-pharyngeal mucositis due to radiation therapy, benzydamine hydrochloride use has provided relief through reduction of pain and edema. Similar studies in patients with acute sore throat demonstrated relief from pain.

## **DETAILED PHARMACOLOGY**

Parenteral benzydamine hydrochloride in animal experiments inhibited morphological symptoms and pain due to various experimental inflammations (produced by carrageenin, serotonin, histamine, yeast, kaolin, dextran, egg albumin, cotton-pellet and croton oil granuloma, acrolein inhalation).

It had relatively little or no effect on Freund's adjuvant arthritis and on erythema produced by UV radiation or x-rays.

The analgesic activity of benzydamine was more pronounced in models involving an experimental inflammation rather than in non-inflammatory pain.

The mechanism of anti-inflammatory action is not related to a stimulation of the pituitary-adrenal axis. Like other non-steroidal anti-inflammatory agents, benzydamine inhibits the biosynthesis of prostaglandins under certain conditions but its properties in this respect have not been fully elucidated.

Benzydamine hydrochloride possesses a local anesthetic activity at low concentrations (0.15-1.0%) as demonstrated by corneal reflex inhibition in rabbits or in human volunteers using benzydamine mouthwash.

Peripheral reflexes were transiently inhibited after i.v. administration to cats.



## TOXICOLOGY

### Acute Toxicity

Route	LD <sub>50</sub> (mg/kg)					
	Mouse	Rat	Rabbit	Cat	Dog	Horse
i.v.	33	--	--	22	29	23
i.p.	110	100	--	--	--	--
s.c.	218	--	--	--	--	--
p.o.	515	1050	400	--	--	--

The acute toxic effects in mice and rats included muscle relaxation, ataxia, and at lethal doses, prostration and clonic convulsions.

### Subacute Toxicity

Benzydamine was administered to rats (Long-Evans) at daily oral doses of 200 mg/kg for 1 month, at increasing doses from 200 to 300 mg/kg over 1 month or from 250 to 500 mg/kg over 3 months, or admixed in the diet (0.5% for 3 months; 0.01% and 0.1% for 6 months). Liver enlargement and a decrease in the growth rate were observed in rats treated with doses of 300 - 500 mg/kg/day or fed with the 0.5% diet. No histological toxic changes were found in the liver or other organs. Seven out of 30 rats died within 5 days of the increase of the daily dose from 250 to 500 mg/kg.

Mice (CF-1) were given a diet containing 0.01% or 0.1% benzydamine for 6 months (approximately 15 and 150 mg/kg). The mice exhibited an increase in liver weight, without histological changes, at the higher concentration. No other pathological alterations were noted.

Dogs were treated with benzydamine 30 mg/kg p.o. for 1 or 6 months. An increase in daily dosage to 45 mg/kg induced vomiting. No changes in behaviour, growth, organ weights, histology, blood counts, urinalysis, SGOT, glucose, BUN, serum electrophoresis and osmotic resistance of RBC were seen.

Topical administration (5% gel) to the rat and rabbit skin for 30 days did not result in any systemic toxicity.

### Chronic Toxicity

Rats (Charles River) were treated daily with oral doses of 0, 10, 50 and 250 mg/kg for 18 months; urinalysis, hematological tests and determinations of fasting blood sugar, BUN, SGOT, SGPT, prothrombin time and coagulation time were performed and found to be within normal limits. High dose females showed hyperactivity. High dose animals showed inhibited growth

rate. There was an increased liver/body weight ratio in males of the highest dosage group. Biochemical and hematological tests yielded normal values.

A 12-month experiment in Rhesus monkeys treated with daily doses of 0, 7, 20 and 60 mg/kg by gavage (10 animals per dose) revealed no pathological alterations in the biochemical and hematological tests performed.

Two animals died after receiving a single dose of 120 mg/kg, while two others were sacrificed in moribund condition after receiving 60 mg/kg per day after three and one-half and thirty-two days, respectively.

### **Local Tolerance**

Rats appeared to be sensitive to skin applications of 5% benzydamine hydrochloride gel for 30 days at 0.5 and 1 g/day. No appreciable irritation was seen on normal or abraded skin of rabbits after application of the same gel for 30 days, or 5% cream for 1 day. Cats, dogs and ponies received a 2-week application of 5% cream to shaved skin without signs of intolerance.

Subcutaneous injections to rats and conjunctival instillations to rabbits produced transient symptoms of irritation after use of concentrations 0.25% and higher.

No sensitization could be demonstrated after repeated intradermal injections (0.1%) to guinea pigs.

### **Reproductive Studies**

Orally administered benzydamine hydrochloride did not increase the incidence of fetal malformations in mice, rats and rabbits. Non-specific skeletal anomalies and retarded ossification were reported in the offspring of mice treated with 100 mg/kg/day s.c. or 240 mg/kg/day p.o. and of rats treated with 150 mg/kg/day s.c., or 240 mg/kg/day p.o. The incidence of dead fetuses was increased in rats, particularly at higher doses (200 and 240 mg/kg/day p.o.).

These findings were accompanied by lower maternal weights in the high dosage groups and were considered as manifestations of maternal toxicity rather than a specific teratogenic effect on fetal development.

## REFERENCES

1. Balato N, Lembo G, Patruno C, Bordone F, Ayala F. Contact dermatitis from benzydamine hydrochloride. *Contact Dermatitis* 1986; 15: 105.
2. Baldock GA, Brodie LF, Chasseaud LF, Taylor T, Walmsley LM. Pharmacokinetics of benzydamine after intravenous, oral, and topical doses to human subjects. *Biopharm Drug Disp* 1991, 12: 481-92.
3. Bruynzeel DP. Contact allergy to benzydamine. *Contact Dermatitis* 1986; 14: 313-14.
4. Catanese B, Grasso A, Silvestrini B. Studies on the absorption and elimination of benzydamine in the mouse, rat, dog and man. *Arzneim Forsch* 1966; 16: 1354-57.
5. Christophersen J. Allergic contact dermatitis to benzydamine. *Contact Dermatitis* 1987; 16: 106-07.
6. *Compendium of Pharmaceuticals and Specialities* 12th Edition 1985; p. 679.
7. Fernandez de Corres L. Photodermatitis from benzydamine. *Contact Dermatitis* 1980; 6: 285.
8. Foti C, Vena GA, Angelini G. Occupational contact allergy to benzydamine hydrochloride. *Contact Dermatitis* 1992; 27: 328-29.
9. Froidevaux A-C. Traitement de la rhinite aigue. Experimentation en double aveugle chez l'adulte d'une solution a 1% de benzydamine en application topique par rapport a un placebo. *Revue Med Suisse Rom.* 1992; 112: 277-80.
10. Froom J. Benzydamine oral rinse for sore throat. *Curr Ther Res* 1979; 26(6): 856-61.
11. Goday Bujan JJ, Ilardia Lorentzen R, Soloeta Arechavala R. Allergic contact dermatitis from benzydamine with probable cross-reaction to indomethacin. *Contact Dermatitis* 1993; 28: 111-12.
12. Harrison RG, O'Donnell PJ. The anti-inflammatory effects of benzydamine. *Toxicol Appl Pharm* 1970; 17: 355-60.
13. Jepson BA. Relieving the pain of pressure sores. *Lancet* 1992; 339: 503-04.
14. Kawaji A, Ohara K, Tababatake E. An assay of flavin- containing monooxygenase activity with benzydamine N-Oxidation. *Biol & Pharm Bull* 1994; 17 (5): 603-06.
15. Lisciani R, Scorza Barcellona P, Silvestrini B. Researches on the topical activity of benzydamine. *Eur J Pharm* 1968 3: 157-62.

16. McQuay HJ, Carroll D, Moxon A, Glynn CJ, Moore RA. Benzylamine cream for the treatment of post-herpetic neuralgia: minimum duration of treatment periods in a cross-over trial. *Pain* 1990; 40: 131-35.
17. Motley RJ, Reynolds AJ. Photodermatitis from benzylamine cream. *Contact Dermatitis* 1988; 19: 66.
18. O'Callaghan CA, Andrews PA, Ogg CS. Renal disease and use of topical non-steroidal anti-inflammatory drugs. *BMJ* 1994; 308: 110-11.
19. Prescribing Information- TANTUM (Benzylamine HCl 0.15% solutions) Oral Rinse - Locally Acting Analgesic Agent. Medicis Canada Ltd., Toronto, Ontario; January 3, 2012, Control # 152324.
20. Scorza Barcellona P, Catanese B. Induzione enzimatica e funzionalità epatica ricerche sulla benzidamina. *Bol Chim Farm* 1966; 105: 367-74.
21. Silvestrini B, Catanese B, Del Basso P. Researches on the increase of liver weight produced by some drugs. *Biochem Pharm* 1966; 15: 249-54.
22. Silvestrini B, Garau A, Pozzatti C, Cioli V. Pharmacological research on benzylamine - a new analgesic- anti-inflammatory drug. *Arzneim Forsch* 1966; 16: 59-63.
23. Silvestrini B, Garau A, Pozzatti C, Cioli V, Catanese B. Additional pharmacological studies on benzylamine. *Arch Int Pharmacodyn* 1966; 163 (1): 61-9.
24. Silvestrini B, Scorza Barcellona P, Catanese B. Toxicology of benzylamine. *Toxicol Appl Pharm* 1967; 10: 148-59.
25. Silvestrini B, Tagliapietra L. Ricerche sperimentali sull'azione disinfettante della benzidamina. *Boll Chim Farm* 1968; 107: 353-61.
26. Simard-Savoie S, Forest D. Topical anesthetic activity of benzylamine. *Curr Ther Res* 1978; 23(6): 734-45.
27. Vermeulen HJ. A clinical investigation on the possible effects of benzylamine hydrochloride on liver function. *Arzneim Forsch* 1970; 20: 767-70.
28. Vincenzi C, Cameli N, Tardio M, Piraccini M. Contact and photocontact dermatitis due to benzylamine hydrochloride. *Contact Dermatitis* 1990; 23: 125-26.

## IMPORTANT: PLEASE READ

### PART III: CONSUMER INFORMATION

#### Pr PHARIXIA®

#### Pr PHARIXIA® ALCOHOL FREE

Benzylamine Mouthwash, BP This leaflet is part III of a three-part "Product Monograph" published when PHARIXIA® and PHARIXIA® ALCOHOL FREE were approved for sale in Canada and are designed specifically for Consumers. This leaflet is a summary and will not tell you everything about PHARIXIA® and PHARIXIA® ALCOHOL FREE. Contact your doctor or pharmacist if you have any questions about the drug.

### ABOUT THIS MEDICATION

#### What the medication is used for:

- the relief of pain in sore throat;
- the relief of symptoms related to mouth and throat mucosa inflammation caused by radiation therapy.

#### What it does:

PHARIXIA® and PHARIXIA® ALCOHOL FREE provide relief by reducing pain and inflammation. PHARIXIA® and PHARIXIA® ALCOHOL FREE act by preventing the formation of chemical messengers named prostaglandins, which are involved in the inflammation process.

#### When it should not be used:

- if you have experienced allergic reactions to any ingredient in PHARIXIA® or PHARIXIA® ALCOHOL FREE;
- in children five years of age and younger;
- if you are pregnant;
- if you have renal disease.

#### What the medicinal ingredient is:

Benzylamine hydrochloride.

#### What the important nonmedicinal ingredients are:

PHARIXIA®: Alcohol, Citric Acid Anhydrous (for pH adjustment), Glycerin, Methylparaben, Natural and Artificial Mouthwash Aroma \*, Polysorbate 80, Propylparaben, Purified Water, Sodium Citrate Dihydrate (for pH adjustment), Sorbitol Solution.

\*Water, Ethyl Alcohol, Natural & Artificial flavour, Polysorbate, Propylene Glycol, D&C Yellow No. 10 and FD&C Blue No. 1

PHARIXIA ALCOHOL FREE: Citric Acid Anhydrous (for pH adjustment), Glycerin, FD&C Yellow No. 6, FD&C Red No. 40, Methylparaben, Natural Orange Flavour\*\*, Polysorbate 80, Propylparaben, Purified Water, Sodium Citrate Dihydrate (for pH adjustment), Sorbitol Solution.

\*\* contains Modified Corn Starch, Corn Syrup, Maltodextrin, Citric Acid, BHT.

#### What dosage forms it comes in:

PHARIXIA® is a mouthwash containing 1.5 mg/mL (0.15% w/v) of benzylamine hydrochloride. It is supplied in bottles of 250 mL. PHARIXIA® is a clear, yellow-green liquid with a mint-like odour.

PHARIXIA® ALCOHOL FREE is a mouthwash containing 1.5 mg/mL (0.15% w/v) of benzylamine hydrochloride. It is supplied in bottles of 250 mL. PHARIXIA® ALCOHOL FREE is a clear light-orange solution.

### WARNINGS AND PRECAUTIONS

**BEFORE you use PHARIXIA® or PHARIXIA® ALCOHOL FREE talk to your doctor or pharmacist if:**

- if you have experienced allergic reactions to any ingredient in PHARIXIA® or PHARIXIA® ALCOHOL FREE;
- if you are pregnant;
- if you have renal disease.

### INTERACTIONS WITH THIS MEDICATION

As with most medicines, interactions with other drugs are possible. Tell your healthcare professional about all the medicines you take, including drugs prescribed by other doctors, vitamins, minerals, natural supplements, or alternative medicines.

### PROPER USE OF THIS MEDICATION

#### Usual Adult Dose:

Radiation Induced Oro-Pharyngeal Mucositis (ulcers in the mouth caused by radiation therapy)

Rinse and gargle the mouth and throat with 15 ml (1 tablespoon) for at least 30 seconds, 3-4 times daily beginning the day prior to starting therapy. Continue use while receiving and after stopping the radiation therapy until symptoms disappear. Spit out the solution. Do Not swallow.

#### Acute Sore Throat

Gargle with 15 ml (1 tablespoon) every 1.5 to 3 hours. Spit out the solution. Do Not swallow.

In case of burning sensation, you can dilute with an equal volume of lukewarm water.

Take exactly as prescribed by your doctor.

#### Overdose:

In case of drug overdose, contact a health care practitioner, hospital emergency department or regional Poison Control

Centre immediately, even if there are no symptoms.

make up the missed dose. Skip the missed dose and continue with the next scheduled dose. Do not double doses.

**Missed Dose:**

If a dose of this medication is missed, it is not necessary to

**IMPORTANT: PLEASE READ**

**SIDE EFFECTS AND WHAT TO DO ABOUT THEM**

**Side effects include:**

- local numbness
- local burning or stinging sensation
- nausea and/or vomiting
- throat irritation
- cough
- dryness of the mouth with thirst
- drowsiness
- headache.

*This is not a complete list of side effects. For any unexpected effects while taking PHARIXIA® or PHARIXIA® ALCOHOL FREE contact your doctor or pharmacist.*

**HOW TO STORE IT**

Store at room temperature (15°C to 30°C). Keep out of reach and sight of children.

**REPORTING SIDE EFFECTS**

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<http://www.hc-sc.gc.ca/dhp-mps/medeff/report-declaration/index-eng.php>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

*NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.*

**MORE INFORMATION**

This document plus the full product monograph, prepared for health professionals can be obtained by contacting the sponsor, PENDOPHARM, Division of Pharmascience Inc., at: 1-888-550-6060.

® Registered Trademark of Pharmascience Inc.

This leaflet was prepared by  
PENDOPHARM, Division of Pharmascience Inc.

Last revised: November 27, 2019.